



31 December 2007

MATTHEW BARNETT STEPS DOWN

Optiscan advises that outgoing CEO, Matthew Barnett will cease to hold a full time executive position as from the close of business today, 31 December 2007. Under the terms of the company's constitution, Mr Barnett also ceases to be a director of the company.

Mr Barnett's departure from the board has been planned since his resignation as CEO was announced in August 2007.

The Board of Optiscan announced on 11 December 2007 that Vicki Tutungi has been appointed as CEO, and will commence on 4 February 2008.

Optiscan Chairman, Mr Grant Latta, said Mr Barnett had provided exemplary service to the company over the past five years.

Mr Barnett will maintain an active association with Optiscan into 2008 to assist incoming CEO Ms Tutungi as required

Background

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Pentax has been licensed by Optiscan to use its patented miniaturised microscope technology in the field of flexible endo-microscopes.

Optiscan has also announced a collaboration with the Carl Zeiss Group in Germany for the use of its patented miniaturised microscope technology in rigid endoscopes in key Zeiss markets.

Further information:

Bruce Andrew, CFO
Tel (613) 9538 3398
brucea@optiscan.com